Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP5L8S)

Drug Name
177Lu-DOTA-octreotate Drug Info
Synonyms
Lutate; Octreotate [177Lu]; Lutetium-177 octreotate; 177-Lu octreotate; 177-Lu-radiolabeled somatostatin receptor-targeted peptide (neuroendocrine tumor), Biosynthema; 177-lutetium-radiolabeled somatostatin receptor-targeted peptide (neuroendocrinetumor), Biosynthema; 177Lutetium DOTA0-Tyr3-Octreotate
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 3 [1]
Neuroendocrine cancer 2B72.1 Phase 3 [2]
Cross-matching ID
PubChem CID
132274234
TTD Drug ID
DMP5L8S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Somatostatin receptor (SSTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
177-Lu-oxodotreotide DMMZS2T Neuroendocrine cancer 2B72.1 Phase 3 [4]
177Lu-DOTATATE DMT8GVU Hepatitis C virus infection 1E51.1 Phase 2 [3]
Somatoprim DMTVS3A Acromegaly 5A60.0 Phase 2 [5]
Edotreotide DMQ08AJ Acromegaly 5A60.0 Phase 2 [6]
FK-962 DMV0MZ3 Alzheimer disease 8A20 Phase 2 [7]
177Lu-labelled DOTA-JR11 DMVZ9XL Neuroendocrine cancer 2B72.1 Phase 1/2 [8]
212Pb-labelled DOTAMTATE DMN9MPX Neuroendocrine cancer 2B72.1 Phase 1 [9]
AlphaMedix DMBVM1Q Neuroendocrine cancer 2B72.1 Phase 1 [10]
FK-960 DMPD8O2 Cognitive impairment 6D71 Discontinued in Phase 2 [7]
SEGLITIDE DMXZVPH Pain MG30-MG3Z Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatostatin receptor (SSTR) TTOMNR9 NOUNIPROTAC Modulator [3]

References

1 ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
4 Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
5 DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
8 Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
9 Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
10 Clinical pipeline report, company report or official report of Orano Med.
11 Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.